Dose equivalence between continuous erythropoietin receptor activator (CERA), Darbepoetin and Epoetin in patients with advanced chronic kidney disease

BACKGROUND: Anemia is a prevalent situation in patients with chronic kidney disease (CKD) and can be well managed with erythropoiesis-stimulating agents (ESAs). Continuous erythropoietin receptor activator (CERA) has a long half-life that allows to be administered once monthly. The lowest recommende...

ver descrição completa

Na minha lista:
Detalhes bibliográficos
Publicado no:Hippokratia
Main Authors: Vega, A, Abad, S, Verdalles, U, Aragoncillo, I, Velazquez, K, Quiroga, B, Escudero, V, López-Gómez, JM
Formato: Artigo
Idioma:Inglês
Publicado em: SOCIETY OF "FRIENDS OF HIPPOKRATIA JOURNAL" 2014
Assuntos:
Original Article
Acesso em linha:https://ncbi.nlm.nih.gov/pmc/articles/PMC4453804/
https://ncbi.nlm.nih.gov/pubmed/26052197
Tags: Adicionar Tag
Sem tags, seja o primeiro a adicionar uma tag!

Registos relacionados